Brief: EMA Grants Orphan Drug Designation To Rafael Pharmaceuticals'Devimistat For Treatment Of Patients With Relapsed Or Refractory Burkitt's Lymphoma
03/11/2021 13:04
Nov 3 (Reuters) - Rafael Holdings Inc RFL.N :
* EUROPEAN MEDICINES AGENCY GRANTS ORPHAN DRUG DESIGNATION
TO
RAFAEL PHARMACEUTICALS' CPI-613® (DEVIMISTAT) FOR TREATMENT OF
PATIENTS WITH RELAPSED OR REFRACTORY BURKITT'S LYMPHOMA
Source text for Eikon: ID:nGNX2j6Wpc
Further company coverage: RFL.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Rafael Holdings
See all newsBrief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million